2023-03-08 16:04:00 ET
- Assertio Therapeutics press release ( NASDAQ: ASRT ): Q4 Non-GAAP EPS of $0.32 beats by $0.12 .
- Revenue of $50.35M (+51.1% Y/Y) beats by $2.91M .
- Adjusted EBITDA increased to $33.4 million, from $17.8 million.
- The Company’s gross profit margin improved by 317 basis points due to continued strong sales of Indocin.
- Cash and cash equivalents at December 31, 2022 was $64.9 million, which reflected $26.7 million of cash flow from operations in the fourth quarter partially offset by $25.0 million of final purchase price payments for Otrexup and Sympazan.
- The Company anticipates revenue in the first quarter of 2023 to be between $36.0 million to $38.0 million, reflecting typical seasonality and the loss of Cambia exclusivity.
- 2023 Outlook: Net Product Sales $150.0 Million to $160.0 Million; Adjusted EBITDA $85.0 Million to $93.0 Millio.
For further details see:
Assertio Therapeutics Non-GAAP EPS of $0.32 beats by $0.12, revenue of $50.35M beats by $2.91M